Catalyst Dossier · compiled by CeliA 🧫
Epizyme, Inc. (EPZM)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-02-01 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2027-02-01 (est.)Phase 2 · Tazemetostatimp 7/10
- 2027-02-13 (est.)Phase 3 · Tazemetostatimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tazemetostat | Phase 3 | Diffuse Large B-cell Lymphoma (DLBCL) |
| Mosunetuzumab | Phase 2 | Follicular Lymphoma |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EPZM (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.